Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Gynecologic 1

Conditions

Colorectal Neoplasms 23Pancreatic Neoplasms 10Colonic Neoplasms 8Stomach Neoplasms 7Esophageal Neoplasms 7Rectal Neoplasms 5Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Adenocarcinoma Of Esophagus 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Cholangiocarcinoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Neoplasms 3Endometrial Neoplasms 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Melanoma 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Urothelial Carcinoma of the Bladder 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Bowel Adenocarcinoma 1Sarcoma, Ewing 1

Interventions

Carboplatin 29pembrolizumab 25Pemetrexed 25Specimen Handling 22Cisplatin 20Magnetic Resonance Spectroscopy 18Paclitaxel 15Gemcitabine 13Docetaxel 12durvalumab 9Nivolumab 8osimertinib 7Taxes 7Immunoglobulin G 7Disulfides 7130-nm albumin-bound paclitaxel 7atezolizumab 6Etoposide 6Platinum 5Cetuximab 51,2-diaminocyclohexaneplatinum II citrate 5X-Rays 4Ramucirumab 4Radiotherapy 4Radiation 4Observation 4Interviews as Topic 4Biopsy 4Albumin-Bound Paclitaxel 4patritumab deruxtecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × Fluorouracil × 30 days × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Pfizer

Phase 1 Terminated
30 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡